Director Waddill’s 10‑b‑5 Purchases and Option Sales Pump $1.1M into Protagonist Therapeutics Ahead of 52‑Week High Surge

Insider Buying Spurs Short‑Term Optimism for Protagonist Therapeutics

On June 10, 2026, Director William D. Waddill executed a 10‑b‑5 plan purchase of 3,000 shares at $11.80 and a second purchase of 6,000 shares at $16.54, raising his post‑transaction holdings to 16,825 shares. The trades were filed on the same day as a Rule 144 sale of 9,000 shares acquired through exercise of stock options, which were sold for cash at $107.68. In total, Waddill’s day‑to‑day activity added roughly $115,000 of equity to the company, while the option sale supplied about $970,000 of cash. The transaction timing—just after a modest 0.04% price gain and a 342 % spike in social‑media buzz—signals that insiders are looking to lock in gains as the stock edges toward its 52‑week high of $111.45.

What This Means for Investors

The immediate market impact is likely muted. The shares bought represent less than 1 % of the float, and the 10‑b‑5 plan limits trading to pre‑set prices, mitigating the risk of a price shock. However, the fact that a director is using the plan to accumulate shares, coupled with a sizable cash inflow from option sales, may be read by price‑action traders as a sign of confidence in the pipeline. Protagonist’s biotech focus on peptide‑based therapeutics has seen a recent uptick in pipeline visibility, and the insider buying could be an attempt to shore up the balance sheet ahead of upcoming clinical milestones. For long‑term investors, the transaction is a positive signal that management believes the company’s valuation is still undervalued relative to its clinical potential.

Waddill’s Historical Trading Patterns

Waddill has a long record of disciplined 10‑b‑5 transactions. His most recent series of trades (May 29 – June 10) shows a pattern of buying in the mid‑$10s and mid‑$15s, followed by sales at higher valuations (up to $107). Over the past 12 months he has accumulated roughly 35,000 shares, with the majority bought at $10–$17 and sold at $80–$110. The timing of his sales—often coinciding with positive earnings announcements or clinical updates—suggests a strategy aimed at capitalizing on short‑term upside while avoiding the risk of insider trading violations. His option sales have consistently been exercised when the market is near a recent high, providing liquidity without exposing the company to market volatility.

Broader Insider Activity

The June 10 filing sits within a broader trend of mixed insider activity at Protagonist. The CEO, Patels, has been buying and selling in the $20–$100 range, while the CFO has been selling large blocks in the $80–$105 range. The recent uptick in social‑media buzz—342 % above average—reflects heightened speculation around upcoming clinical data. Waddill’s buying, occurring just after the surge, may be interpreted by the market as a “buy the rumor” move, potentially reinforcing a bullish stance for the next quarter.

Bottom Line

Insider buying by a director via a 10‑b‑5 plan is a conventional but reassuring signal that management believes the company is undervalued, especially amid a positive clinical narrative. For investors, the transaction is a low‑impact trade that may hint at future upside, but the real test will come when Protagonist delivers on its peptide pipeline and the stock reacts to the forthcoming clinical data releases.